Trial Profile
A Randomized, Placebo-Controlled Phase II Study of Vismodegib (GDC-0449, Systemic Hedgehog Antagonist) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 18 Oct 2012 Final results published in the Clinical Cancer Research.
- 17 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.